mTOR signaling: new networks for ALL

Por Fruman, David A.
Publicado no Blood (2016)

A LIPID KINASE COUSIN COOPERATES TO PROMOTE CANCER

Por Beagle, Brandon, Fruman, David A.
Publicado em 2011

PI3K Signaling in B and T Lymphocytes: New Developments and Therapeutic Advances

Por So, Lomon, Fruman, David A.
Publicado em 2012

PI3K and Cancer: Lessons, Challenges and Opportunities

Por Fruman, David A., Rommel, Christian
Publicado em 2014

PI3Ks IN LYMPHOCYTE SIGNALING AND DEVELOPMENT

Por Okkenhaug, Klaus, Fruman, David A.
Publicado no Curr Top Microbiol Immunol (2010)

Targeting TOR dependence in cancer

Por Janes, Matthew R., Fruman, David A.
Publicado em 2010

Akt and mTOR in B Cell Activation and Differentiation

Por Limon, Jose J., Fruman, David A.
Publicado em 2012

Achieving cancer cell death with PI3K/mTOR-targeted therapies

Por Yea, Sung Su, Fruman, David A.
Publicado em 2013

Idelalisib — A PI3Kδ Inhibitor for B-Cell Cancers

Por Fruman, David A., Cantley, Lewis C.
Publicado em 2014

Too much of a good thing: immunodeficiency due to hyperactive PI3K signaling

Por Walsh, Craig M., Fruman, David A.
Publicado em 2014

INPP4B is a tumor suppressor in the context of PTEN deficiency

Por Vo, Thanh-Trang T., Fruman, David A.
Publicado no Cancer Discov (2015)

Context-specific function of S6K2 in helper T cell differentiation()

Por Pai, Christine, Walsh, Craig M., Fruman, David A.
Publicado no J Immunol (2016)

Targeting mTOR for the treatment of B cell malignancies

Por Lee, Jong‐Hoon Scott, Vo, Thanh‐Trang, Fruman, David A.
Publicado no Br J Clin Pharmacol (2016)

Transformation of Mouse Fibroblasts by Jaagsiekte Sheep Retrovirus Envelope Does Not Require Phosphatidylinositol 3-Kinase

Por Maeda, Naoyoshi, Inoshima, Yasuo, Fruman, David A., Brachmann, Saskia M., Fan, Hung
Publicado em 2003

The p85β regulatory subunit of phosphoinositide 3-kinase has unique and redundant functions in B cells

Por OAK, JEAN S., CHEN, JING, PERALTA, RAECHEL Q., DEANE, JONATHAN A., FRUMAN, DAVID A.
Publicado em 2009

FOXO1 REGULATES MARGINAL ZONE B CELL DEVELOPMENT

Por Chen, Jing, Limon, Jose J., Blanc, Caroline, Peng, Stanford L., Fruman, David A.
Publicado em 2010

MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma

Por Lee, J. Scott, Tang, Sarah S., Ortiz, Veronica, Vo, Thanh-Trang, Fruman, David A.
Publicado no Oncotarget (2015)

Phosphoinositide 3-kinase and Bruton's tyrosine kinase regulate overlapping sets of genes in B lymphocytes

Por Fruman, David A., Ferl, Gregory Z., An, Sam S., Donahue, Amber C., Satterthwaite, Anne B., Witte, Owen N.
Publicado em 2002

S6 kinase 2 potentiates interleukin-3-driven cell proliferation

Por Cruz, Rebecca, Hedden, Lee, Boyer, Derek, Kharas, Michael G., Fruman, David A., Lee-Fruman, Kay K.
Publicado em 2005

Resistance to mTOR Kinase Inhibitors in Lymphoma Cells Lacking 4EBP1

Por Mallya, Sharmila, Fitch, Briana A., Lee, J. Scott, So, Lomon, Janes, Matthew R., Fruman, David A.
Publicado em 2014